VistaGen
San Francisco
About VistaGen
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS). VistaGen's lead product candidate, AV-101, is a next generation, orally available prodrug candidate in Phase 2 development, initially for the adjunctive treatment of Major Depressive Disorder (MDD) in patients with an inadequate response to standard antidepressants.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $154.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2023)
- Ticker: nasdaq:VTGN
- Website: vistagen.com
- Phone: +1-650-577-3600
Industries & Categories
Biotechnology, Clinical Trials, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/vistagen-415 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.